Keywords : therapeutics, Therapy, therapeutic classe
The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by G...
More »
Search ReportLinker
The Largest Collection of Market Research Reports
» 1.2 Million Industry Reports
» 450,000 Company Profiles
» 850,000 Market Briefings
» 40,000 Country Guides
From +200,000 authoritative sources
- Publication date: December 2010
- Report price: $ 500
The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.
Scope of the Research
- Massachusetts Eye and Ear Infirmary - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Massachusetts Eye and Ear Infirmary human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Massachusetts Eye and Ear Infirmary with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Massachusetts Eye and Ear Infirmary’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Why Should You Get This Report?
- Evaluate Massachusetts Eye and Ear Infirmary’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Massachusetts Eye and Ear Infirmary in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Massachusetts Eye and Ear Infirmary’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Massachusetts Eye and Ear Infirmary.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Massachusetts Eye and Ear Infirmary and identify potential opportunities in those areas.
Therapy Industry in the United States
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Massachusetts Eye and Ear Infirmary Snapshot 5
Massachusetts Eye and Ear Infirmary Overview 5
Key Information 5
Key Facts 5
Massachusetts Eye and Ear Infirmary – Research and Development Overview 6
Key Therapeutic Areas 6
Massachusetts Eye and Ear Infirmary – Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products – Monotherapy 10
Pipeline Products – Combination Treatment Modalities 11
Massachusetts Eye and Ear Infirmary – Pipeline Products Glance 12
Massachusetts Eye and Ear Infirmary – Late Stage Pipeline 12
Phase III Products/Combination Treatment Modalities 12
Massachusetts Eye and Ear Infirmary Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Massachusetts Eye and Ear Infirmary – Drug Profiles 15
Methylprednisolone Sodium Succinate 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Prednisone 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Propranolol 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Proton Pump Inhibitor 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
2.5% Interleukin-1-Receptor Antagonist 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
5% Interleukin-1-Receptor Antagonist 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Avastin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
IL-1Ra 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ranibizumab 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Ranibizumab + Proton Beam Irradiation 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Massachusetts Eye and Ear Infirmary – Pipeline Analysis 25
Massachusetts Eye and Ear Infirmary – Pipeline Products by Therapeutic Class 25
Massachusetts Eye and Ear Infirmary Pipeline Products By Target 27
Massachusetts Eye and Ear Infirmary – Pipeline Products by Route of Administration 29
Massachusetts Eye and Ear Infirmary – Pipeline Products by Molecule Type 31
Massachusetts Eye and Ear Infirmary – Locations And Subsidiaries 32
Head Office 32
Recent Developments 33
March 29, 2010: Health Canada Approves Roche's AVASTIN For Treatment Of Glioblastoma Multiforme 33
March 29, 2010: Health Canada Approves Roche's AVASTIN For Treatment Of Glioblastoma Multiforme 33
March 15, 2010: Roche's Phase III study Of Avastin In Men With Late Stage Prostate Cancer Fails Endpoint 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 36
Contact Us 36
Disclaimer 36List of Tables
Massachusetts Eye and Ear Infirmary – Pipeline by Therapy Area and Indication, 2010 8
Massachusetts Eye and Ear Infirmary – Pipeline by Stage of Development, 2010 9
Massachusetts Eye and Ear Infirmary – Monotherapy Products in Pipeline, 2010 10
Massachusetts Eye and Ear Infirmary – Combination Treatment Modalities in Pipeline, 2010 11
Massachusetts Eye and Ear Infirmary – Phase III, 2010 12
Massachusetts Eye and Ear Infirmary - Phase II, 2010 13
Massachusetts Eye and Ear Infirmary - Phase I, 2010 14
Massachusetts Eye and Ear Infirmary - Pipeline By Therapeutic Class, 2010 25
Massachusetts Eye and Ear Infirmary - Pipeline By Target, 2010 28
Massachusetts Eye and Ear Infirmary – Pipeline By Route of Administration, 2010 30
Massachusetts Eye and Ear Infirmary – Pipeline By Molecule Type, 2010 31
List of Figures
Massachusetts Eye and Ear Infirmary – Pipeline by Therapy Area and Indication, 2010 7
Massachusetts Eye and Ear Infirmary – Pipeline by Stage of Development, 2010 9
Massachusetts Eye and Ear Infirmary – Monotherapy Products in Pipeline, 2010 10
Massachusetts Eye and Ear Infirmary – Combination Treatment Modalities in Pipeline, 2010 11
Massachusetts Eye and Ear Infirmary – Pipeline By Therapeutic Class, 2010 25
Massachusetts Eye and Ear Infirmary - Pipeline By Target, 2010 27
Massachusetts Eye and Ear Infirmary – Pipeline By Route of Administration, 2010 29
Massachusetts Eye and Ear Infirmary – Pipeline By Molecule Type, 2010 31
- Publication date: December 2010
- Report price: $ 500
